Cancer rarely announces its changes with drama. It moves in metrics, scans, and clinical notes. And as much as I have learned to read my body through each step of my many long walks, fasting windows, heart rate, and sleep, the real story often arrives through the documents that land in my Princess Margaret chart.<\/p>\n\n\n\n
This week, I received two new updates \u2014 one on December 8 and another on December 10 \u2014 each adding another layer of clarity as I start treatment and begin a clinical trial. Together, they confirm something important: my cancer remains confined, measurable, and stable enough to move forward \u2014 and so am I.<\/strong><\/p>\n\n\n\n The outcomes from these last two visits to Princess Margaret have reaffirmed the same core message I\u2019ve lived with since tumour recurrence was confirmed:<\/p>\n\n\n\n In cancer terms, this is geography I can work with. Territory where I can fight.<\/p>\n\n\n\n The outcome of today’s visit note also reiterated what my team has consistently stated: I am a candidate for standard-of-care FOLFIRI + Panitumumab, but my physical condition and disease profile make me equally, if not better, suited for the GSK5764227<\/a><\/strong> clinical trial.<\/p>\n\n\n\n The washout period is complete. The screening is passed. The slot is open.<\/p>\n\n\n\n The December 10 visit with the trial oncology team was the last piece of the puzzle before treatment could begin. It documented my bloodwork from the same day \u2014 normal glucose, normal chloride, a clean panel \u2014 and officially listed metastatic colon adenocarcinoma<\/strong> as the diagnosis.<\/p>\n\n\n\n Metastatic colon adenocarcinoma<\/strong> is advanced, stage 4 colon cancer<\/strong> that has spread (metastasized) from the colon to distant parts of the body, most commonly the liver, lungs, peritoneum, or distant lymph nodes, via the bloodstream or lymphatic system. While often not curable, treatments like chemotherapy, targeted therapy, immunotherapy, and surgery aim to control it, extend life, and improve quality, with outcomes varying wildly depending on treatment response and cancer characteristics.<\/p>\n<\/div>\n<\/div>\n\n\n\n There\u2019s something quietly powerful about seeing my chart evolve from \u201cassessment\u201d to \u201caction.\u201d When I look at these summaries, I don\u2019t see administration. I see orientation \u2014 a map of where I am as Chapter Four<\/a> <\/strong>continues.<\/p>\n\n\n\n They reaffirm several truths I hold onto:<\/p>\n\n\n\n This isn\u2019t the picture of someone fighting from behind. This is someone stepping into treatment with strength, clarity, and intention.<\/p>\n\n\n\n For weeks, everything has been preparation: scans, ECGs, echocardiograms, bloodwork, fasting protocols, long walking days, sauna cycles, sleep discipline, and the mental sorting that comes with knowing a new therapy is approaching.<\/p>\n\n\n\n But now the tone changes.<\/p>\n\n\n\n There is no more \u201cif the trial slot opens.\u201d All of that is settled. The path is chosen.<\/p>\n\n\n\n Tomorrow, I sit down in a chair at Princess Margaret, and the first infusion of GSK5764227 goes into my bloodstream. The fight becomes chemical. Targeted. Directed. Real, in a way, it hasn\u2019t been since April.<\/p>\n\n\n\nA Clear Picture of Where I Stand<\/strong><\/h2>\n\n\n\n
\n
December 10: The Final Check Before the First Infusion<\/strong><\/h2>\n\n\n\n
My participation in the GSK5764227 trial is no longer theoretical. It is scheduled.<\/p>\n\n\n\nWhy These Updates Matter<\/strong><\/h2>\n\n\n\n
\n
The Shift From Waiting to Doing<\/strong><\/h2>\n\n\n\n
No more \u201cif screening passes.\u201d
No more \u201cif the team agrees.\u201d<\/p>\n\n\n\nChapter Four Continues<\/strong><\/h2>\n\n\n\n